DOCSLIB.ORG

2-Pentadecyl-2-Oxazoline Ameliorates Memory

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2-Pentadecyl-2-Oxazoline Ameliorates Memory Boccella et al. Mol Brain (2021) 14:28 https://doi.org/10.1186/s13041-020-00724-z RESEARCH Open Access 2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors Serena Boccella1†, Francesca Guida1†, Monica Iannotta1†, Fabio Arturo Iannotti3,4†, Rosmara Infantino1, Flavia Ricciardi1, Claudia Cristiano2, Rosa Maria Vitale3, Pietro Amodeo3, Ida Marabese1, Carmela Belardo1, Vito de Novellis1, Salvatore Paino1, Enza Palazzo1, Antonio Calignano2, Vincenzo Di Marzo3,4,5, Sabatino Maione1,4,6 and Livio Luongo1,4,6* Abstract Neuropathic pain (NP) remains an untreatable disease due to the complex pathophysiology that involves the whole pain neuraxis including the forebrain. Sensory dysfunctions such as allodynia and hyperalgesia are only part of the symptoms associated with neuropathic pain that extend to memory and afectivity defcits. The development of multi-target molecules might be a promising therapeutic strategy against the symptoms associated with NP. 2-penta- decyl-2-oxazoline (PEA-OXA) is a plant-derived agent, which has shown efectiveness against chronic pain and associ- ated neuropsychiatric disorders. The molecular mechanisms by which PEA-OXA exerts its efects are, however, only partially known. In the current study, we show that PEA-OXA, besides being an alpha2 adrenergic receptor antagonist, also acts as a modulator at histamine H3 receptors, and report data on its efects on sensory, afective and cognitive symptoms associated with the spared nerve injury (SNI) model of neuropathic pain in mice. Treatment for 14 days with PEA-OXA after the onset of the symptoms associated with neuropathic pain resulted in the following efects: (i) allodynia was decreased; (ii) afective/cognitive impairment associated with SNI (depression, spatial, and working memories) was counteracted; (iii) long-term potentiation in vivo in the lateral entorhinal cortex-dentate gyrus (per- forant pathway, LPP) was ameliorated, (iv) hippocampal glutamate, GABA, histamine, norepinephrine and dopamine altered levels after peripheral nerve injury were reversed, (v) expression level of the TH positive neurons in the Locus Coeruleus were normalized. Thus, a 16-day treatment with PEA-OXA alleviates the sensory, emotional, cognitive, elec- trophysiological and neurochemical alterations associated with SNI-induced neuropathic pain. Keywords: Neuropathic pain, Depression, Cognitive impairments, H3 receptors, Locus coeruleus, Mice *Correspondence: [email protected] Introduction † Serena Boccella, Francesca Guida, Monica Iannotta and Fabio Arturo In the last two decades, many investigations have been Iannotti share the frst authorship 1 Department of Experimental Medicine, Pharmacology Division, focused towards plastic changes at supra-spinal corti- University of Campania “L. Vanvitelli”, 80138 Naples, Italy cal [1–3] and non-cortical structures [4, 5] underlying Full list of author information is available at the end of the article cognitive/afective consequences of neuropathic pain. © The Author(s) 2021 corrected publication 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Boccella et al. Mol Brain (2021) 14:28 Page 2 of 24 Although the infuence of neuropathic pain on hip- agonists in neuropathic pain can be partially mediated by pocampal structures began to be studied many dec- α2 adrenoceptor desensitization [23] inspired us to eval- ades ago [6], only recently it has become the subject of uate possible anti-neuropathic properties of PEA-OXA more in-depth studies by several laboratories [7–10] Te and investigate the possible involvement of H3 receptor. involvement of the hippocampus in spatial memory dis- In the present study, we frst checked whether PEA- orders and other comorbidities of neuropathic pain was OXA was also able to modulate the activity of histamine recently shown also in the spared nerve injury (SNI) H3 receptors in vitro. Indeed, this compound belongs to model of neuropathic pain [7]. SNI impairs synaptic plas- a large family of long chain fatty acid-derived biologi- ticity (LTP or STP) at hippocampal dentate gyrus (DG), cally active mediators with multiple molecular targets CA1, and CA3 synapses [7–10], as well as DG neurogen- [31]. Once that its pharmacological activity at the hista- esis [7, 11]. Te entorhinal cortex-hippocampus pathway mine H3 receptor was demonstrated for the frst time, we plays a pivotal role in persistent pain such that cortical evaluated the efect of repeated administrations (16 days projections to the hippocampus can diferently afect starting the treatment 14 days after sciatic nerve surgery) pain perception [12, 13] Te interactions between the of PEA-OXA on: (i) mechanical allodynia, (ii) afective lateral entorhinal cortex (LEC) and the DG are in charge and cognitive (spatial and working memory) behavior, with the integration of important emotional stimuli asso- (iii) neural activity in the LC, (iv) in vivo long term poten- ciated with space–time orientation and place memory tiation in the entorhinal-cortex/dentate gyrus, LPP, and storage [14]. Among the several neurotransmitters and (iv) glutamate, GABA, norepinephrine, dopamine and neuromodulators that orchestrate the complex scenario histamine levels in the hippocampus. All the behavioral, in forebrain chronic pain mechanisms, the glutamater- biochemical and electrophysiological experiments were gic (Glu), GABAergic and the endocannabinoid (eCB) carried out in control and neuropathic mice 30 days after systems have been deeply investigated [2, 15–18]. Fur- the sham or SNI surgery on the sciatic nerve. thermore, a key role of the biogenic amines (i.e. norepi- nephrine, dopamine, serotonin, histamine, etc.) has been Materials and methods highlighted in both chronic pain and some of its mala- Homology modelling of histamine H3 receptor daptive neuroplasticities [19]. Te noradrenergic projec- Te sequences of the histamine H3 receptor was retrieved tions modulating pain originate from cell nuclei in the from the publicly available sequence database www. unipr brainstem, namely the locus coeruleus (LC), A5, and ot. org (UNIPROT: Q9Y5N1). 50 homology models of A7 cell groups [20, 21]. In particular, the noradrenergic receptor were built with MODELLER [32, 33] version system in the LC seems to play a key role in the main- 9.14 using the x-ray structure of the acetylcholine M3 tenance of neuropathic pain-induced allodynia [22]. receptor (PDB id: 4U15) as a template and the structural Like norepinephrine, histamine is gaining great interest alignment. Te best model in term of both Modeller in the central mechanisms of neuroplasticity underlying Objective Function and Dope score was selected for the neuropathic pain [23, 24]. In addition to the known seda- subsequent docking calculations. tive efect of histamine H1 receptor antagonists, interest today has focused on histamine H3 receptors [24–26], Ligand building which, by being expressed at the level of the presynap- To carry out the docking calculations, the starting ligand tic terminals, strongly infuence the release of histamine geometry of histamine and PEA-OXA was built with and various neurotransmitters [27–29]. Although his- UCSF Chimera 1.14 [34] and energy minimized at molec- tamine H3 receptor blockade has been shown to relieve ular mechanics level, using AM1-BCC charges and then neuropathic pain [25, 26], the role of this receptor and optimized using GAMESS program [35] at the Hartree– the mechanisms underlying its supraspinal efects on the Fock level with STO-3G basis set, followed by a single- various components of neuropathic pain are still poorly point HF energy evaluation at the 6-31G* level to derive understood. We recently investigated the behavioral the partial atomic charges for the ligands using the RESP efects of 2-pentadecyl-2-oxazoline (PEA-OXA), a natu- procedure [36]. ral compound found in green and roasted cofee beans, in a murine model of mild traumatic brain injury (mTBI), Molecular docking which develops into a neuro-psychiatric syndrome very Docking studies were performed with AutoDock 4.2 often observed in post-traumatic states. In that study, it [36, 37]. H3 model along with the ligands was pro- was found that the in vitro and in vivo efects of PEA- cessed with AutoDock Tools (ADT) package version OXA were mediated by its action as an antagonist on the 1.5.6rc123 to merge non-polar hydrogens, calculate norepinephrine alpha2 receptor [30]. Te evidence that Gasteiger charges and select rotatable sidechain bonds. the analgesic efects of H3 receptor antagonists/inverse A 60 Å × 60 Å × 70 Å grid, centred in the orthosteric Boccella et al. Mol Brain (2021) 14:28 Page 3 of 24 Fig. 1 Alpha2-mediated efect of PEA-OXA in vitro and in vivo. (a) Scatter plots showing the efect of PEA-OXA in COS cells stably expressing histamine H3 receptors on intracellular cAMP levels. Forskolin 10 μM served as AMPc inducer. Data represent the mean S.E.M. of four separate ± determinations. Data sets were compared using t-Test and ANOVA followed by Tukey’s test. The asterisk indicates a p value 0.05 vs vehicle.
Load more

Recommended publications
  • A Guide to Glutamate Receptors
    A guide to glutamate receptors 1 Contents Glutamate receptors . 4 Ionotropic glutamate receptors . 4 - Structure ........................................................................................................... 4 - Function ............................................................................................................ 5 - AMPA receptors ................................................................................................. 6 - NMDA receptors ................................................................................................. 6 - Kainate receptors ............................................................................................... 6 Metabotropic glutamate receptors . 8 - Structure ........................................................................................................... 8 - Function ............................................................................................................ 9 - Group I: mGlu1 and mGlu5. .9 - Group II: mGlu2 and mGlu3 ................................................................................. 10 - Group III: mGlu4, mGlu6, mGlu7 and mGlu8 ............................................................ 10 Protocols and webinars . 11 - Protocols ......................................................................................................... 11 - Webinars ......................................................................................................... 12 References and further reading . 13 Excitatory synapse pathway
    [Show full text]
  • The G Protein-Coupled Glutamate Receptors As Novel Molecular Targets in Schizophrenia Treatment— a Narrative Review
    Journal of Clinical Medicine Review The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment— A Narrative Review Waldemar Kryszkowski 1 and Tomasz Boczek 2,* 1 General Psychiatric Ward, Babinski Memorial Hospital in Lodz, 91229 Lodz, Poland; [email protected] 2 Department of Molecular Neurochemistry, Medical University of Lodz, 92215 Lodz, Poland * Correspondence: [email protected] Abstract: Schizophrenia is a severe neuropsychiatric disease with an unknown etiology. The research into the neurobiology of this disease led to several models aimed at explaining the link between perturbations in brain function and the manifestation of psychotic symptoms. The glutamatergic hypothesis postulates that disrupted glutamate neurotransmission may mediate cognitive and psychosocial impairments by affecting the connections between the cortex and the thalamus. In this regard, the greatest attention has been given to ionotropic NMDA receptor hypofunction. However, converging data indicates metabotropic glutamate receptors as crucial for cognitive and psychomotor function. The distribution of these receptors in the brain regions related to schizophrenia and their regulatory role in glutamate release make them promising molecular targets for novel antipsychotics. This article reviews the progress in the research on the role of metabotropic glutamate receptors in schizophrenia etiopathology. Citation: Kryszkowski, W.; Boczek, T. The G Protein-Coupled Glutamate Keywords: schizophrenia; metabotropic glutamate receptors; positive allosteric modulators; negative Receptors as Novel Molecular Targets allosteric modulators; drug development; animal models of schizophrenia; clinical trials in Schizophrenia Treatment—A Narrative Review. J. Clin. Med. 2021, 10, 1475. https://doi.org/10.3390/ jcm10071475 1. Introduction Academic Editors: Andreas Reif, Schizophrenia is a common debilitating disease affecting about 0.3–1% of the human Blazej Misiak and Jerzy Samochowiec population worldwide [1].
    [Show full text]
  • Review Article Development of PET and SPECT Probes for Glutamate Receptors
    Hindawi Publishing Corporation e Scientific World Journal Volume 2015, Article ID 716514, 19 pages http://dx.doi.org/10.1155/2015/716514 Review Article Development of PET and SPECT Probes for Glutamate Receptors Takeshi Fuchigami, Morio Nakayama, and Sakura Yoshida Department of Hygienic Chemistry, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan Correspondence should be addressed to Takeshi Fuchigami; [email protected] Received 28 June 2014; Accepted 29 August 2014 Academic Editor: Masahiro Ono Copyright © 2015 Takeshi Fuchigami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. l-Glutamate and its receptors (GluRs) play a key role in excitatory neurotransmission within the mammalian central nervous system (CNS). Impaired regulation of GluRs has also been implicated in various neurological disorders. GluRs are classified into two major groups: ionotropic GluRs (iGluRs), which are ligand-gated ion channels, and metabotropic GluRs (mGluRs), which are coupled to heterotrimeric guanosine nucleotide binding proteins (G-proteins). Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of GluRs could provide a novel view of CNS function and of a range of brain disorders, potentially leading to the development of new drug therapies. Although no satisfactory imaging agents have yet been developed for iGluRs, several PET ligands for mGluRs have been successfully employed in clinical studies. This paper reviews current progress towards the development of PET and SPECT probes for GluRs. 1.
    [Show full text]
  • Ultra-Micronized Palmitoylethanolamide Rescues The
    Neurobiology of Disease 121 (2019) 106–119 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Ultra-micronized palmitoylethanolamide rescues the cognitive decline- associated loss of neural plasticity in the neuropathic mouse entorhinal T cortex-dentate gyrus pathway Serena Boccellaa,1, Claudia Cristianob,1, Rosaria Romanoa, Monica Iannottaa, Carmela Belardoa, Antonio Farinaa, Francesca Guidaa, Fabiana Piscitellic, Enza Palazzoa, Mariacristina Mazzitellid, Roberta Imperatoree, Lea Tunisic, Vito de Novellisa, Luigia Cristinoc, Vincenzo Di Marzoc, ⁎ Antonio Calignanob, Sabatino Maionea, Livio Luongoa, a Department of Experimental Medicine, Pharmacology Division, University of Campania “L. Vanvitelli”, 80138 Naples, Italy b Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy c Endocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR, Pozzuoli, Italy d Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX e Department of Science and Technology, University of Sannio, Benevento, Italy ARTICLE INFO ABSTRACT Keywords: Chronic pain is associated with cognitive deficits. Palmitoylethanolamide (PEA) has been shown to ameliorate Spared nerve injury pain and pain-related cognitive impairments by restoring glutamatergic synapses functioning in the spared nerve pamitoylethanolamide injury (SNI) of the sciatic nerve in mice. SNI reduced mechanical and thermal threshold, spatial memory and LTP long term potentiation at the lateral entorhinal cortex (LEC)-dentate gyrus (DG) pathway. It decreased also postsynaptic density, vo- PPARα lume and dendrite arborization of DG and increased the expression of metabotropic glutamate receptor 1 and 7 cognitive performance (mGluR1 and mGluR7), of the GluR1, GluR1s845 and GluR1s831 subunits of AMPA receptor and the levels of synaptogenesis glutamate in the DG.
    [Show full text]
  • Addiction Research Tools
    Addiction Research Tools Cayman offers a wide range of products to study targeted brain circuits mediating the behavioral effects of drugs of abuse. We also offer over 2,000 high-quality analytical standards that have been synthesized using a range of analytical techniques to verify identity, purity, and other relevant characteristics. Whether you are looking to quickly identify or quantify drugs of abuse via mass spec or understand their physiological and toxicological properties, Cayman has the right tools to help make your research possible. DopamineDopamine transportertransporters s DopamineDopamine Drugs Drugs DopamineDopamine receptorresceptors Drugs of Abuse Amphetamines and Other Stimulants Benzodiazepines Item No. Product Name Item No. Product Name 15650 D-Amphetamine (hydrochloride) (exempt preparation) 15287 α-hydroxy Alprazolam 10488 Bupropion (hydrochloride) 14263 Clonazepam 15655 (–)-(S)-Cathinone (hydrochloride) (exempt preparation) 18173 Clonazolam 22165 Cocaine (hydrochloride) 15554 Diclazepam 11159 Dimethocaine (hydrochloride) 15889 Estazolam 11630 Ketamine (hydrochloride) 24481 Flualprazolam 13971 3,4-MDMA (hydrochloride) 11449 Ketazolam 15657 Mephedrone (hydrochloride) (exempt preparation) 15891 Lorazepam 15656 Methcathinone (hydrochloride) (exempt preparation) 16193 Midazolam 14276 PCP (hydrochloride) 22577 Triazolam Over 650 amphetamine and other stimulant standards available online Over 100 benzodiazepine standards available online Addiction Research Products are available in BULK quantities to qualified institutions
    [Show full text]
  • Metabotropic Glutamate Receptor 7 Modulates the Rewarding Effects of Cocaine in Rats: Involvement of a Ventral Pallidal Gabaergic Mechanism
    Neuropsychopharmacology (2009) 34, 1783–1796 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org Metabotropic Glutamate Receptor 7 Modulates the Rewarding Effects of Cocaine in Rats: Involvement of a Ventral Pallidal GABAergic Mechanism 1 1 1 1 1 ,1 Xia Li , Jie Li , Xiao-Qing Peng , Krista Spiller , Eliot L Gardner and Zheng-Xiong Xi* 1Neuropsychopharmacology Section, Chemical Biology Research Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA The metabotropic glutamate receptor 7 (mGluR7) has received much attention as a potential target for the treatment of epilepsy, major depression, and anxiety. In this study, we investigated the possible involvement of mGluR7 in cocaine reward in animal models of drug addiction. Pretreatment with the selective mGluR7 allosteric agonist N,N’-dibenzyhydryl-ethane-1,2-diamine dihydrochloride (AMN082; 1-20 mg/kg, i.p.) dose-dependently inhibited cocaine-induced enhancement of electrical brain-stimulation reward and intravenous cocaine self-administration under both fixed-ratio and progressive-ratio reinforcement conditions, but failed to alter either basal or cocaine-enhanced locomotion or oral sucrose self-administration, suggesting a specific inhibition of cocaine reward. Microinjections of AMN082 (1–5 mg/ml per side) into the nucleus accumbens (NAc) or ventral pallidum (VP), but not dorsal striatum, also inhibited cocaine self-administration in a dose-dependent manner. Intra-NAc or intra-VP co-administration of 6-(4-methoxyphenyl)-5-methyl-3-pyridin- 4-ylisoxazolo[4,5-c]pyridin-4(5H)-one (MMPIP, 5 mg/ml per side), a selective mGluR7 allosteric antagonist, significantly blocked AMN082’s action, suggesting an effect mediated by mGluR7 in these brain regions.
    [Show full text]
  • Development of PET and SPECT Probes for Glutamate Receptors
    NAOSITE: Nagasaki University's Academic Output SITE Title Development of PET and SPECT Probes for Glutamate Receptors Author(s) Fuchigami, Takeshi; Nakayama, Morio; Yoshida, Sakura Citation The Scientific World Journal, 2015, 716514; 2015 Issue Date 2015 URL http://hdl.handle.net/10069/35383 © 2015 Takeshi Fuchigami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits Right unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This document is downloaded at: 2020-01-27T20:29:52Z http://naosite.lb.nagasaki-u.ac.jp Hindawi Publishing Corporation e Scientific World Journal Volume 2015, Article ID 716514, 19 pages http://dx.doi.org/10.1155/2015/716514 Review Article Development of PET and SPECT Probes for Glutamate Receptors Takeshi Fuchigami, Morio Nakayama, and Sakura Yoshida Department of Hygienic Chemistry, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan Correspondence should be addressed to Takeshi Fuchigami; [email protected] Received 28 June 2014; Accepted 29 August 2014 Academic Editor: Masahiro Ono Copyright © 2015 Takeshi Fuchigami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. l-Glutamate and its receptors (GluRs) play a key role in excitatory neurotransmission within the mammalian central nervous system (CNS). Impaired regulation of GluRs has also been implicated in various neurological disorders. GluRs are classified into two major groups: ionotropic GluRs (iGluRs), which are ligand-gated ion channels, and metabotropic GluRs (mGluRs), which are coupled to heterotrimeric guanosine nucleotide binding proteins (G-proteins).
    [Show full text]
  • Pathogenic GRM7 Mutations Associated With
    Research Articles: Cellular/Molecular Pathogenic GRM7 mutations associated with neurodevelopmental disorders impair axon outgrowth and presynaptic terminal development https://doi.org/10.1523/JNEUROSCI.2108-20.2021 Cite as: J. Neurosci 2021; 10.1523/JNEUROSCI.2108-20.2021 Received: 11 August 2020 Revised: 11 January 2021 Accepted: 16 January 2021 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2021 the authors 1 Pathogenic GRM7 mutations associated with neurodevelopmental 2 disorders impair axon outgrowth and presynaptic terminal 3 development 4 Abbreviation title: Pathogenic GRM7 mutations 5 6 Jae-man Song1,2,3, Minji Kang1,2,3, Da-ha Park1,2,3, Sunha Park1,2,3, Sanghyeon Lee1,2,3, and 7 Young Ho Suh1,2,3,* 8 1Department of Biomedical Sciences, 2Neuroscience Research Institute, 3Transplantation 9 Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea 10 11 *Corresponding Author: Young Ho Suh, Department of Biomedical Sciences, Seoul National 12 University College of Medicine, Room 405 Convergence Research Building, 103 Daehak-ro, 13 Jongno-gu, Seoul 03080, South Korea. Tel.: +82-2-3668-7611; E-mail: [email protected] 14 15 Number of pages: 43 16 Number of figures: 10 17 Number of table: 1 18 Number of words for abstract: 248 19 Number of words for introduction: 649 20 Number of words for discussion: 1464 21 22 Conflict of interest: The authors have no conflict of interest to declare.
    [Show full text]
  • Constitutive Activity of Metabotropic Glutamate Receptor 7 Paul J Kammermeier
    Kammermeier BMC Neuroscience (2015) 16:17 DOI 10.1186/s12868-015-0154-6 RESEARCH ARTICLE Open Access Constitutive activity of metabotropic glutamate receptor 7 Paul J Kammermeier Abstract Background: Metabotropic glutamate receptors (mGluRs) are class C G protein coupled receptors with widespread central nervous system expression. mGluR7 is a member of this family that has been implicated in numerous physiological and pathological processes, but the very low potency of mGluR7 for glutamate, its natural ligand, raise questions about the nature of its physiological role. Results: Here, evidence is presented using heterologous expression in sympathetic neurons from the rat superior cervical ganglion (SCG) and modulation of the native SCG calcium currents as an assay for receptor signaling, that mGluR7 exhibits constitutive activity. This activity is detectable as basal calcium channel modulation in the absence of ligand that is not observed in untransfected cells or those transfected with other members of the mGluR family. Further, this basal channel modulation was reversibly inhibited with the mGluR7 inverse agonist MMPIP. Surprisingly, MMPIP did not strongly inhibit agonist-induced mGluR7 activation. Finally, the selective mGluR8 agonist (R,S)-PPG was also able to act as an inverse agonist at mGluR7. Conclusions: These findings introduce a novel potential physiological role for mGluR7 in the nervous system, that of a constitutively active receptor, and thereby suggest a model in which mGluR7 signaling may be impactful without the need to invoke strong receptor activation by millimolar concentrations of extracellular glutamate. Constitutive activity of mGluR7 may be eliminated or reduced by the presence of other group III mGluRs, perhaps due to heterodimer formation.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION MMPIP (hydrochloride) Item No. 18862 CAS Registry No.: 1215566-78-1 O Formal Name: 6-(4-methoxyphenyl)-5- methyl-3-(4-pyridinyl)- isoxazolo[4,5-c]pyridin-4(5H)-one, O monohydrochloride N N MF: C19H15N3O3 • HCl FW: 369.8 O Purity: ≥98% Supplied as: A solid • HCl Storage: Room temperature Stability: ≥1 year N Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures MMPIP (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the MMPIP (hydrochloride) in the solvent of choice, which should be purged with an inert gas. MMPIP (hydrochloride) is soluble in the organic solvent DMSO at a concentration of approximately 10 mM. Description MMPIP is a reversible allosteric antagonist of the metabotropic glutamate receptor 7 (mGluR7) that 1,2 blocks agonist-induced calcium mobilization (IC50 = 26 nM). It does not affect other mGlu receptors. The modulation of mGluR7 by MMPIP is context dependent, in that it is not observed in all known mGluR7 signaling pathways.2 MMPIP has been used to investigate the role of mGluR7 in cocaine-mediated reward signaling, attention and impulse control, and cognitive behavior in mice and rats.3-5 MMPIP also reversibly inhibits constitutive activity of mGluR7 in sympathetic neurons from the rat superior cervical ganglion.6 References 1. Suzuki, G., Tsukamoto, N., Fushiki, H., et al. In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists. J. Pharmacol. Exp. Ther. 323(1), 147-156 (2007). 2. Niswender, C.M., Johnson, K.A., Miller, N.R., et al.
    [Show full text]
  • Effects of a Metabotropic Glutamate Receptor Subtype 7 Negative Allosteric Modulator in the Periaqueductal Grey on Pain Response
    Palazzo et al. Molecular Pain 2013, 9:44 http://www.molecularpain.com/content/9/1/44 MOLECULAR PAIN RESEARCH Open Access Effects of a metabotropic glutamate receptor subtype 7 negative allosteric modulator in the periaqueductal grey on pain responses and rostral ventromedial medulla cell activity in rat Enza Palazzo1*, Ida Marabese2, Livio Luongo2, Serena Boccella2, Giulia Bellini2, Maria Elvira Giordano2, Francesca Rossi3, Mariantonietta Scafuro1, Vito de Novellis2 and Sabatino Maione2* Abstract The metabotropic glutamate receptor 7 (mGluR7) negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3- pyridin-4-ylisoxazolo[4,5-c]pyridin-4(5H)-one (MMPIP), was locally microinjected into the ventrolateral periaqueductal gray (VL PAG) and the effect on pain responses in formalin and spare nerve injury (SNI) -induced neuropathic pain models was monitored in the rat. The activity of rostral ventromedial medulla (RVM) “pronociceptive” ON and “antinociceptive” OFF cells was also evaluated. Intra–VL PAG MMPIP blocked the first and second phase of nocifensive behaviour in the formalin pain model. MMPIP increased the tail flick latency and simultaneously increased the activity of the OFF cells while inhibiting that of ON cells in rats with SNI of the sciatic nerve. MMPIP failed to modify nociceptive responses and associated RVM ON and OFF cell activity in sham rats. An increase in mGluR7 gene, protein and staining, the latter being associated with vesicular glutamate transporter-positive profiles, has been found in the VL PAG in SNI rats. Blockade of mGluR7 within the VL PAG has an antinociceptive effect in formalin and neuropathic pain models. VL PAG mGluR7 blockade offers a target for dis-inhibiting the VL PAG-RVM pathway and silencing pain in inflammatory and neuropathic pain models.
    [Show full text]
  • The Role of G Protein-Coupled Receptors (Gpcrs) and Calcium Signaling in Schizophrenia
    cells Review The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines Tomasz Boczek 1 , Joanna Mackiewicz 1 , Marta Sobolczyk 1 , Julia Wawrzyniak 1, Malwina Lisek 1, Bozena Ferenc 1, Feng Guo 2 and Ludmila Zylinska 1,* 1 Department of Molecular Neurochemistry, Faculty of Health Sciences, Medical University of Lodz, 92215 Lodz, Poland; [email protected] (T.B.); [email protected] (J.M.); [email protected] (M.S.); [email protected] (J.W.); [email protected] (M.L.); [email protected] (B.F.) 2 Department of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang 110122, China; [email protected] * Correspondence: [email protected] Abstract: Schizophrenia is a common debilitating disease characterized by continuous or relapsing episodes of psychosis. Although the molecular mechanisms underlying this psychiatric illness remain incompletely understood, a growing body of clinical, pharmacological, and genetic evidence suggests that G protein-coupled receptors (GPCRs) play a critical role in disease development, progression, and treatment. This pivotal role is further highlighted by the fact that GPCRs are the most common Citation: Boczek, T.; Mackiewicz, J.; targets for antipsychotic drugs. The GPCRs activation evokes slow synaptic transmission through 2+ Sobolczyk, M.; Wawrzyniak, J.; Lisek, several downstream pathways, many of them engaging intracellular Ca mobilization. Dysfunctions M.; Ferenc, B.; Guo, F.; Zylinska, L. of the neurotransmitter systems involving the action of GPCRs in the frontal and limbic-related The Role of G Protein-Coupled regions are likely to underly the complex picture that includes the whole spectrum of positive Receptors (GPCRs) and Calcium and negative schizophrenia symptoms.
    [Show full text]